Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls.
Hua-Jay J CherngJason R WestinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Tafasitamab and lenalidomide were approved for second-line treatment of diffuse large B-cell lymphoma (DLBCL) based on a single-arm phase II study. This combination was superior to routine immunochemotherapy regimens when comparing matched observational cohorts. "Synthetic" control groups may support use of novel DLBCL therapies in the absence of randomized studies. See related article by Nowakowski et al., p. 4003.
Keyphrases
- diffuse large b cell lymphoma
- phase ii study
- open label
- epstein barr virus
- multiple myeloma
- placebo controlled
- newly diagnosed
- double blind
- stem cell transplantation
- phase ii
- locally advanced
- phase iii
- clinical trial
- chronic lymphocytic leukemia
- squamous cell carcinoma
- cross sectional
- randomized controlled trial
- case control
- low dose
- study protocol